Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | USP14 | P54578 | 2/20 | 0.36 |
| ▸ | TDP2 | O95551 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HK1 | P19367 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146452 | 0.83 | MEN1 (0.36) | ESR2USP14TDP2EGFRSRC | |
| SCHEMBL2146618 | 0.82 | USP14 (0.34) | USP14TDP2EGFRSRCKDM4E | |
| SCHEMBL2146608 | 0.80 | USP14 (0.39) | USP14EGFRSRCKDM4ESTAT3 | |
| SCHEMBL30385406 | 0.79 | AGTR1 (0.46) | ESR2EGFRSRCKDM4EESR1 | |
| SCHEMBL1075323 | 0.79 | AGTR1 (0.46) | ESR2EGFRSRCKDM4EESR1 | |
| SCHEMBL28285318 | 0.76 | IL1R1 (0.46) | ESR2EGFRSRCKDM4EESR1 | |
| SCHEMBL2146338 | 0.76 | ESR2 (0.42) | ESR2TDP2KDM4EESR1ALDH1A1 | |
| SCHEMBL30385665 | 0.73 | EGFR (0.42) | ESR2EGFRSRCKDM4EESR1 | |
| SCHEMBL1077219 | 0.73 | EGFR (0.42) | ESR2EGFRSRCKDM4EESR1 | |
| SCHEMBL1076542 | 0.71 | EGFR (0.41) | ESR2USP14EGFRSRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | claimed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | claimed |
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | disclosed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ESR2 4/4885USP14 3060/4885TDP2 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.